ArticlePCN reports : psychiatry and clinical neurosciences2025
Perampanel-associated exacerbation of de novo psychosis and lateralized rhythmic delta activity: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perampanel-associated exacerbation of de novo psychosis and lateralized rhythmic delta activity: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perampanel (PER) may instigate psychiatric phenomena encompassing irritability and aggression. This study elucidates an epileptic patient in whom PER appeared to exacerbate preexisting psychosis, concomitant with lateralized rhythmic delta activity (LRDA). Case Presentation: A 30-year-old right-handed female initially exhibited focal aware seizures and focal to bilateral tonic-clonic seizures at 21 years of age. Despite administration of multiple antiseizure medications (ASM), she continued to experience weekly seizure episodes. At the age of 26 years, she underwent right selective amygdalohippocampectomy (SeAH) concurrent with vagus nerve stimulation (VNS) implantation. Following this intervention, the seizure frequency diminished from weekly to monthly, albeit not entirely eliminated. Five months postoperatively, the patient displayed paranoid delusions and auditory hallucinations. Her psychotic symptoms were assessed as de novo psychosis. In July of year Y-1, PER was coadministered with Valproic acid, Lacosamide, and Levetiracetam to optimize seizure control, with the dosage escalated to 6 mg by December of year Y-1. Simultaneously, in July of year Y, heightened irritability, aggression, and psychomotor agitation became prominent, necessitating hospitalization in August of year Y. An electroencephalogram (EEG) upon admission revealed LRDA over the right posterior quadrant. Subsequent cessation of PER administration culminated in the resolution of both exacerbated psychiatric symptoms and LRDA within approximately a week. Conclusion: The observed LRDA in this case may represent cerebral dysregulation, possibly induced by PER, concurrent with the worsening of psychiatric sequelae. Psychosis during PER treatment could signify underlying brain dysfunction, highlighting the potential utility of EEG monitoring in managing these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.